Search Results - "Dentico, P."

Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04 by Boland, G., Beran, J., Lievens, M., Sasadeusz, J., Dentico, P., Nothdurft, H., Zuckerman, J.N., Genton, B., Steffen, R., Loutan, L., Hattum, J. Van, Stoffel, M.

“…The reactogenicity and safety of an experimental hepatitis B (HB) vaccine containing adjuvant system (AS04) was compared with a licensed vaccine in a phase…”
Get full text

Viral hepatitis, HIV, human herpes virus and Treponema pallidum infection in haemodialysis patients from Kosovo, 2005 by Quaglio, G L, Pattaro, C, Ramadani, N, Bertinato, L, Elezi, Y, Dentico, P, Volpe, A, Ciotti, M, Rezza, G, Putoto, G

“…The serological status of hepatitis viruses and other infectious diseases in the 66 dialysed patients of one haemodialysis unit in Kosovo were studied,…”
Get full text

Intestinal Parasites in Healthy Subjects in Albania by Spinelli, R., Brandonisio, O., Serio, G., Trerotoli, P., Ghezzani, F., Carito, V., Dajçi, N., Doçi, A., Picaku, F., Dentico, P.

“…The purpose of this study was to evaluate the prevalence of intestinal parasites in 277 healthy subjects in the city of Mamuras (Albania, South Eastern Europe)…”
Get full text

Hepatitis B Virus Infection in Health Care Workers in Albania: a Country still Highly Endemic for HBV Infection by Kondili, L. A, Ulqinaku, D, Hajdini, M, Basho, M, Chionne, P, Madonna, E, Taliani, G, Candido, A, Dentico, P, Bino, S, Rapicetta, M

“…Background: Health care workers (HCW) have an elevated risk of acquiring and transmitting parenteral infections. The aim of this study was to evaluate the…”
Get full text

Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117) by Fiorentini, G., Rossi, S., Lanzanova, G., Bernardeschi, P., Dentico, P., De Giorgi, U.

Get full text

Helicobacter pylori Seroprevalence in Selected Groups of Albanian Volunteers by Monno, R., Volpe, A., Basho, M., Fumarola, L., Trerotoli, P., Kondili, L. A., Bino, S., Schinaia, N., Dentico, P.

“…Background: Albania is a Mediterranean, South–East European developing country where epidemiological data on infectious diseases are scarce. In this study, the…”
Get full text

Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records by Bernardeschi, P, Fiorentini, G, Dentico, P, Rossi, S, Turrisi, G, Del Conte, A, Giannessi, P G, Giustarini, G, Montenora, I

Get full text

The pharmacokinetics of oral cephalosporins by Mazzei, T., Dentico, P.

Get full text

Intra-Arterial Hepatic Chemoembolization in Liver Metastases from Neuroendocrine Tumors: A Phase II Study by Fiorentini, G., Rossi, S., Bonechi, F., Vaira, M., De Simone, M., Dentico, P., Bernardeschi, P., Cantore, M., Guadagni, S.

“…Neuroendocrine tumors, particularly those of gastrointestinal tract origin, have a predisposition for metastasizing to the liver, causing parenchymal…”
Get full text

Thalidomide plus Monthly High-dose Dexamethasone in Chemorefractory Myeloma. Results of a Phase II Clinical Study by Bernardeschi, P, Giustarini, G, Montenora, I, Turrisi, G, Dentico, P, Rossi, S, Turano, E, Fiorentini, G

“…Thalidomide is a potent anti-myeloma drug which can produce up to a 30-50% overall response rate (ORR) in pre-treated, chemorefractory multiple myeloma. Most…”
Get full text

Trisomy 8 in Philadelphia‐negative cells during imatinib therapy by Bernardeschi, P., Fiorentini, G., Rossi, S., Dentico, P., Simi, P., Guidi, S.

“…Targeted therapy with imatinib selectively suppresses Philadelphia‐positive cells in chronic myeloid leukemia cells, with reappearance of apparently normal…”
Get full text

Reactogenicity and immunogenicity of a new combined Measles–Mumps–Rubella vaccine: results of a multicentre trial by Crovari, P., Gabutti, G., Giammanco, G., Dentico, P., Moiraghi, A.R., Ponzio, F., Soncini, R.

“…A large single blind, multi-centre study involving 1779 children was performed in Italy. Infants, aged between 12 and 27 months were divided between two…”
Get full text

First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer by Fiorentini, G, Tsetis, D, Bernardeschi, P, Varveris, C, Rossi, S, Kalogeraki, A, Athanasakis, E, Dentico, P, Kanellos, P, Biancalani, M, Almarashdah, S, Zacharioudakis, G, Saridaki, Z, Chalkiadakis, G, Xynos, E, Zoras, O

“…Approximately 20% of patients with breast cancer present with locally advanced disease without distant metastases. This phase II double-center trial aimed at…”
Get more information

Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma by Bemardeschi, P, Dentico, P, Rossi, S, Fiorentini, G, Giustarini, G, Turano, E

“…Thalidomide is active both as single agent and in combination-therapy against refractory or relapsing multiple myeloma. Eigth patients previously treated were…”
Get more information

Immunogenicity and Reactogenicity following Primary Immunisation with a Combined DTaP-HBV Vaccine and a Haemophilus influenzae Type B Vaccine Administered by Separate or Mixed Injection by Gabutti, G, Bona, G, Dentico, P, Bamfi, F, Hardt, K, Majori, S, Crovari, P

“…The aim of this open, randomised, multicentre trial was to evaluate the immunogenicity and reactogenicity of the tetravalent diphtheria-tetanus-acellular…”
Get full text

Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study by Martoni, A, Mini, E, Pinto, C, Gentile, A L, Nobili, S, Dentico, P, Marino, A, Scicolone, S, Angelelli, B, Mazzei, T

“…The combination of Oxaliplatin (OXA) and Raltitrexed (RTX) may represent a more convenient regimen as compared with OXA + 5-FU with Folinic acid (FA)…”
Get more information

Chemoresistant Myeloma: Phase II Clinical Study with Low-Dose Thalidomide Plus High-Dose Dexamethasone by Bernardeschi, P., Dentico, P., Rossi, S., Fiorentini, G., Giustarini, G., Montenora, I., Turano, E.

“…Thalidomide produces a response rate from 32 to 66% of pre-treated myeloma patients with doses ranging from 100 to 800 mg/daily. Common, dose-related side…”
Get full text

Efficacy of imatinib mesylate in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy with epirubicin by Fiorentini, G, Bernardeschi, P, De Simone, M, Rossi, S, Dentico, P, Biancalani, M, Scuderi, S, Vaira, M, Palomba, A

Get more information

Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma by Martoni, A., Mini, E., Pinto, C., Nobili, S., Gentile, A. L., Dentico, P., Angelelli, B., Scicolone, S., Piana, E., Mazzei, T.

“…Background Both OHP and 5-FU are clinically active as single agents in the treatment of metastatic colorectal cancer (MCRC) Clinical and laboratory studies…”
Get full text

Hepatic Intra-Arterial Chemotherapy (HIAC) of High Dose Mitomycin and Epirubicin Combined with Caval Chemofiltration Versus Prolonged Low Doses in Liver Metastases from Colorectal Cancer: a Prospective Randomized Clinical Study by Fiorentini, G., Poddie, D.B., Cantore, M., Rossi, S., Tumolo, S., Dentico, P., Bernardeschi, P., Guadagni, S., Rossi, G., Valori, V.M., De Simone, M.

“…A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval…”
Get full text